Novo Nordisk (NVO) is planning to boost its investment in Ireland where it will make its Wegovy weight-loss pill for markets outside the US, Bloomberg reported Thursday, citing an interview with Mike Doustdar, the company's CEO.
The company will expand its facility in Athlone to manufacture the weight-loss drug, Doustdar said.
Novo Nordisk didn't immediately respond to MT Newswires' request for comment.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Price: 48.17, Change: -0.58, Percent Change: -1.18